Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Dan Passeri - Chief Executive Officer Anish Suri - President & Chief Scientific Officer Matteo Levisetti - Chief Medical Officer Kerri Millar - Chief Financial Officer Conference Call Participants Ted Tenthoff - Piper Sandler Ren Benjamin - JMP Securities Operator Greetings, and welcome to the Cue Biopharma Investor Update Call. At this time, all participants are in a listen-only mode. A question ...

| --- | --- | --- | --- | --- | |-------------------------------------|-------|-----------------------|------------|---------------------| | | | June 30, 2023 \n(in | thousands) | December 31, 2022 | | Laboratory equipment | $ | 5,205 | $ | 5,246 | | Furniture and fixtures | | 81 | | 81 | | Computer and office equipment | | 296 | | 296 | | Leasehold improvements | | 118 | | 118 | | | | 5,699 | | 5,741 | | Less accumulated depreciation | | (4,507 | ) | (4,242 ) | | Net property and equipment | $ | 1,192 | $ ...

Principal Commitments As a smaller reporting company, we are not required to provide the information required by this Item 3. Inherent Limitations on Effectiveness of Controls PART II. OTHER INFORMATION We operate in a rapidly changing environment that involves a number of risks that could materially affect our business, financial condition or future results, some of which are beyond our control. The occurrence of any of these risks could harm our business, financial condition, results of operations and/or ...

Cue Biopharma, Inc. (NASDAQ:CUE) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Dan Passeri - CEO Matteo Levisetti - Chief Medical Officer Ken Pienta - Clinical Advisory Anish Suri - President and Chief Scientific Officer Kerri Millar - CFO Sara Pai - Surgical Oncologist and Director, Translational Head and Neck Cancer Research, Mass General Hospital Conference Call Participants Ted Tenthoff - Piper Sandler Ren Benjamin - JMP Securities Mark Breidenbach - Oppenheimer Stephen ...

WASHINGTON, D.C. 20549 Cue Biopharma, Inc. 02135 (ZipCode) Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act): Yes ☐ No ☒ The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, as of the last business day of the registrant's most recently completed second fiscal quarter, was approximately $82.1 million (based on the closing price of the registrant's common stock on June 30, 2022 of $2.49 per share). ...

Call Start: 16:30 January 1, 0000 5:23 PM ET Cue Biopharma, Inc. (NASDAQ:CUE) Q3 2022 Earnings Conference Call November 14, 2022 16:30 ET Company Participants Dan Passeri - Chief Executive Officer Anish Suri - President & Chief Scientific Officer Ken Pienta - Acting Chief Medical Officer Matteo Levisetti - Senior Vice President of Clinical Development Kerri Millar - Chief Financial Officer Conference Call Participants Reni Benjamin - JMP Securities Stephen Willey - Stifel Mark Breidenbach - Oppenheimer Ted ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-38327 Cue Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 47-3324577 (State or other jurisd ...

Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2022 Earnings Conference Call August 23, 2022 4:30 PM ET Company Participants Dan Passeri - Chief Executive Officer Anish Suri - President & Chief Scientific Officer Ken Pienta - Acting Chief Medical Officer Matteo Levisetti - SVP, Clinical Development Kerri Millar - Chief Financial Officer Conference Call Participants Stephen Willey - Stifel Reni Benjamin - JMP Securities Mark Breidenbach - Oppenheimer Operator Greetings and welcome to the Cue Biopharma Update Call. At t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-38327 Cue Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 47-3324577 (State or other jurisdictio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-38327 Cue Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 47-3324577 (State or other jurisdicti ...